Your browser doesn't support javascript.
loading
Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line.
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W; Perez-Villarroel, Patricio; Nakagawa, Ryosuke; Falahat, Rana; Berglund, Anders E; Mulé, James J.
Afiliação
  • Zhu G; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Nemoto S; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Mailloux AW; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Perez-Villarroel P; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Nakagawa R; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Falahat R; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
  • Berglund AE; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
  • Mulé JJ; Immunology Program, Moffitt Cancer Center, Tampa, FL, United States.
Front Immunol ; 9: 1609, 2018.
Article em En | MEDLINE | ID: mdl-30061886
ABSTRACT
Tertiary lymphoid structures (TLSs) associate with better prognosis in certain cancer types, but their underlying formation and immunological benefit remain to be determined. We established a mouse model of TLSs to study their contribution to antitumor immunity. Because the stroma in lymph nodes (sLN) participates in architectural support, lymphogenesis, and lymphocyte recruitment, we hypothesized that TLSs can be created by sLN. We selected a sLN line with fibroblast morphology that expressed sLN surface markers and lymphoid chemokines. The subcutaneous injection of the sLN line successfully induced TLSs that attracted infiltration of host immune cell subsets. Injection of MC38 tumor lysate-pulsed dendritic cells activated TLS-residing lymphocytes to demonstrate specific cytotoxicity. The presence of TLSs suppressed MC38 tumor growth in vivo by improving antitumor activity of tumor-infiltrating lymphocytes with downregulated immune checkpoint proteins (PD-1 and Tim-3). Future engineering of sLN lines may allow for further enhancements of TLS functions and immune cell compositions.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos